RNA Stock Forecast: Atrium Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.92

The median 12-month analyst price target for Atrium Therapeutics, Inc. is $25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 8 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$149.3M
Ticker Nerd rank
8/ 100
Median analyst target
$25
Analysts covering
5
Revenue$3.0M
Operating income−$22.6M
Net income−$20.2M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Atrium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
8/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
83
Quality
17
Value
15
Issuance
14
Growth
10
Momentum
6
Accruals
5
Volatility
4

Revisions (83): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNA, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$15
Low
$25
Median
$25
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Oct 2026HC Wainwright & Co.MaintainsBuy$25 → $20
22 Oct 2026Roth CapitalInitiatesBuy$15
14 Aug 2026HC Wainwright & Co.ReiteratesBuy$25
6 Aug 2026HC Wainwright & Co.InitiatesBuy$25
18 June 2026Cantor FitzgeraldInitiatesOverweight$25
15 May 2026Leerink PartnersInitiatesOutperform—
11 Mar 2026Wells FargoInitiatesOverweight—
11 Nov 2025Chardan CapitalMaintainsNeutral—
29 Oct 2025TD CowenDowngradeHold—
28 Oct 2025Chardan CapitalDowngradeNeutral—
28 Oct 2025RBC CapitalDowngradeSector Perform—
27 Oct 2025BernsteinDowngradeMarket Perform—
27 Oct 2025CitigroupDowngradeNeutral—
27 Oct 2025HC Wainwright & Co.DowngradeNeutral—
27 Oct 2025Leerink PartnersDowngradeMarket Perform—
27 Oct 2025NeedhamDowngradeHold—
27 Oct 2025Raymond JamesDowngradeMarket Perform—
22 Sept 2025Evercore ISI GroupMaintainsOutperform—
17 Sept 2025Roth CapitalInitiatesBuy—
15 Sept 2025B of A SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RNA.

Market Radar

This page is one stock. Monday covers all of them.

RNA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

RNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.8×

Cheaper than 28% of US stocks

Price / book
0.6×

Cheaper than 85% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
24.2%

Higher than 74% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−95.0%

Higher than 14% of US stocks

Return on assets
−34.8%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Atrium Therapeutics, Inc. has a market value of $149.3M.

  • Revenue in the twelve months to 30 June 2026: $35.8M.

  • Net income over the same four quarters: −$93.2M, a −260.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$56.5M.

  • Shares outstanding: 17.1M.

  • Atrium Therapeutics, Inc. employs 511 people — $70K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

RNA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNAAtrium Therapeutics, Inc.$149.3M8
VRXAVERAXA Biotech AG$153.6M18
IFRXInflaRx NV$153.2M11
ORMPOramed Pharmaceuticals, Inc.$148.5M66
PRQRProQR Therapeutics NV$146.8M47
PALIPalisade Bio, Inc.$146.4M19
BBOTBridgebio Oncology Therapeutics, Inc.$145.1M22

Take a look at RNA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Atrium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RNA

What is the RNA stock price forecast for 2026-2027?

The median 12-month analyst price target for Atrium Therapeutics, Inc. is $25, with estimates ranging from $15 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNA stock a buy right now?

Of the 5 analysts covering Atrium Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atrium Therapeutics, Inc. 8 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNA?

As at 21 Nov 2026, Atrium Therapeutics, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).

Will RNA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $25, and Ticker Nerd's factor model ranks Atrium Therapeutics, Inc. 8 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNA stock forecast for 2030?

No analyst covering Atrium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $25 over the next 12 months.

What does Atrium Therapeutics, Inc. do?

Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision.

Company

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision. Its current pipeline centers on rare genetic cardiomyopathies, including ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Atrium Therapeutics also advances research programs aimed at additional rare cardiac conditions, reflecting its focus on genetically defined diseases with significant unmet medical need. Based in San Diego, California, Atrium Therapeutics operates as a specialist developer in the broader biotechnology sector, with a business model centered on translating RNA science into potential treatments for inherited heart disorders.

CEO Ms. Kathleen P. Gallagher · 511 employees · United States · https://atriumtherapeutics.com